New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
14:51 EDTBCRXBioCryst price target raised to $17 from $13 at JMP Securities
JMP Securities raised BioCryst's price target to $17 following proof of concept results for OPuS-1 Phase 2a trial. Shares are Outperform rated.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
07:00 EDTBCRXBioCryst awarded $35M contract by BARDA for development of BCX4430
BioCryst Pharmaceuticals announced that the Biomedical Advanced Research and Development Authority, or BARDA, within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, or ASPR, has awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This ASPR/BARDA contract includes a base contract of $12.1M to support BCX4430 drug manufacturing, as well as $22.9M in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0M. Filoviruses represent serious threats to national security and the U.S. Government has made this a top priority for medical countermeasure development.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use